Results 11 to 20 of about 861 (122)

Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors [PDF]

Cancer Medicine
Background Sapanisertib is a potent ATP‐competitive, dual inhibitor of mTORC1/2. Ziv‐aflibercept is a recombinant fusion protein comprising human VEGF receptor extracellular domains fused to human immunoglobulin G1.
Niamh Coleman, Bettzy Stephen, Siqing Fu, Daniel Karp, Vivek Subbiah, Jordi Rodon Ahnert, Sarina A. Piha‐Paul, John Wright, Senait N. Fessahaye, Fengying Ouyang, Bulent Yilmaz, Funda Meric‐Bernstam, Aung Naing   +12 more
doaj   +3 more sources

Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population. [PDF]

Eye (Lond), 2022
To investigate the use of intravitreal ziv-aflibercept (IVZ) in Ghanaian patients with diabetic macular edema (DME).A retrospective study of patients with DME, who had been treated with IVZ (1.25 mg/0.05 ml), as part of routine clinical practice, on pro re nata basis between 2016 and 2018 who had a minimum follow-up of 6 months was retrieved and ...
Braimah IZ, Amoaku WM.
europepmc   +3 more sources

Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes [PDF]

Journal of Ophthalmic & Vision Research, 2023
Purpose: To evaluate the effects of intravitreal ziv-aflibercept injections (IVZ) on subfoveal choroidal thickness (SCT) as well as on central macular thickness (CMT) and on best corrected visual acuity (BCVA) changes in eyes with center-involved ...
Siamak Moradian, Masoud Soheilian, Mahsan Asadi, Abdolreza Baghi, Hamid Safi, Seyed-Hossein Abtahi   +5 more
doaj   +2 more sources

Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding [PDF]

International Journal of Retina and Vitreous, 2018
Purpose To investigate the binding affinity, stability, and sterility of aflibercept and ziv-aflibercept to vascular endothelial growth factor (Holash et al. in Proc Natl Acad Sci USA 99(17):11393–11398, 2002.
Julia de Lima Farah, Ronaldo Sano, Ieda Maria Longo Maugéri, Daniela Teixeira, Mayari Eika Ishimura, Gabriela Martins, Lycia M. J. Mimica, Cely Barreto da Silva, Carsten H. Meyer, João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Michel Eid Farah   +11 more
doaj   +2 more sources

A combination of suprachoroidal injection of triamcinolone using a custom-made needle and intravitreal Ziv-aflibercept every eight weeks to manage naïve/denovo central DME: a single-center retrospective case series [PDF]

International Journal of Retina and Vitreous
Background Previous studies have shown promising effects of combining intravitreal bevacizumab and suprachoroidal injection of triamcinolone acetonide in treating DME. However, further research is needed.
Ameen Marashi, Marwa Baba, Sedra Abu Ghedda, Mohammad Nour Kitaz, Aya Zazo   +4 more
doaj   +2 more sources

Ziv-aflibercept in macular disease. [PDF]

Br J Ophthalmol, 2015
Aflibercept is an approved therapy for neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DME). In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using the approved cancer protein, ziv-aflibercept.
Mansour AM, Al-Ghadban SI, Yunis MH, El-Sabban ME.   +3 more
europepmc   +4 more sources

Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases [PDF]

Journal of Current Ophthalmology, 2017
Purpose: To investigate the short-term outcomes after intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases.
Kamran HodjatJalali, Shiva Mehravaran, Hooshang Faghihi, Hassan Hashemi, Pegah Kazemi, Hadith Rastad   +5 more
doaj   +2 more sources

Regression in polypoidal choroidal vasculopathy treated with ziv-aflibercept monotherapy - short term study. [PDF]

Saudi J Ophthalmol, 2021
PURPOSE: The aim of this study was to evaluate the effectiveness of intravitreal ziv-aflibercept (IVZ) in the treatment of polypoidal choroidal vasculopathy (PCV) and its efficacy in regard to polyp regression using optical coherence tomography (OCT) and indocyanine green angiography (ICGA ...
Mishra SB, Singh SR, Goyal P, Chakurkar R, Govindhari V, Goud A, Chhablani J.   +6 more
europepmc   +3 more sources

Osteonecrosis of the jaw associated with ziv-aflibercept. [PDF]

J Gastrointest Oncol, 2016
Medication-related osteonecrosis of the jaw (MRONJ) has been associated with medications that include bisphosphonates (BPs), denosumab, bevacizumab and sunitinib. Ziv-aflibercept is a recombinant human vascular endothelial growth factor (VEGF) receptor which has been used to treat patients with various advanced solid tumors.
Mawardi H, Enzinger P, McCleary N, Manon R, Villa A, Treister N, Woo SB.   +6 more
europepmc   +4 more sources

One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion [PDF]

American Journal of Ophthalmology Case Reports, 2017
Purpose: To report the 12-month efficacy and safety outcomes of intravitreal ziv-aflibercept in macular edema secondary to central retinal vein occlusion (CRVO).
Mohab Eldeeb, Errol W. Chan, Chintan J. Dedhia, Ahmad Mansour, Jay Chhablani   +4 more
doaj   +2 more sources